Nanoengineered therapy aiming at the etiology of rheumatoid arthritis

Li, Ruiqi; Ma, Yu; Hong, Jin Pyo; Ding, Ya

doi:10.1016/j.nantod.2021.101367

Cited by 25 publications

(13 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the central role of M1 macrophages in the pathogenesis of RA, efficient repolarization of M1 macrophages to the anti-inflammatory M2 phenotype has become a viable strategy for RA treatment. − For instance, Wen Zhou et al proposed that silver nanoparticles could target M1 macrophages via the folic acid (FA) receptor to reprogram their polarization state . Interestingly, recent insights increasingly reveal that the elevated ROS production in M1 macrophages is a multifaceted driver of RA pathophysiology . On one hand, due to their high biochemical reactivity, the abundant ROS would elicit severe damage to the DNA and proteins to cause cellular injury and cartilage damage. − On the other hand, it could also regulate the TLR/nuclear factor κB (NF-κB) activation in M1 macrophages to amplify the inflammation. − Consequently, normalizing the redox homeostasis in M1 macrophages could yield complementary benefits for RA treatment, which may not only reduce the ROS-mediated direct tissue damage but also reprogram them into anti-inflammatory M2 phenotypes to treat inflammatory diseases. , …”

Section: Introductionmentioning

confidence: 99%

Redox Homeostasis Strategy for Inflammatory Macrophage Reprogramming in Rheumatoid Arthritis Based on Ceria Oxide Nanozyme-Complexed Biopolymeric Micelles

Zhou

Chen

et al. 2023

ACS Nano

View full text Add to dashboard Cite

The synovial tissues under rheumatoid arthritis conditions are usually infiltrated by inflammatory cells, particularly M1 macrophages with aberrant redox homeostasis, which causes rapid deterioration of articular structure and function. Herein, we created an ROS-responsive micelle (HA@RH-CeO X ) through the in situ host–guest complexation between ceria oxide nanozymes and hyaluronic acid biopolymers, which precisely delivered nanozyme and clinically approved rheumatoid arthritis drug Rhein (RH) to proinflammatory M1 macrophage populations in inflamed synovial tissues. The abundant cellular ROS could cleave the thioketal linker to trigger the release of RH and Ce. Specifically, the Ce3+/Ce4+ redox pair could present SOD-like enzymatic activity to rapidly decompose ROS and alleviate the oxidative stress in M1 macrophages, while RH could inhibit the TLR4 signaling in M1 macrophages, both of which could act in a concerted manner to induce their repolarization into anti-inflammatory M2 phenotype to ameliorate local inflammation and promote cartilage repair. Notably, rats bearing rheumatoid arthritis showed a drastic increase in the M1-to-M2 macrophage ratio from 1:0.48 to 1:1.91 in the inflamed tissue and significantly reduced inflammatory cytokine levels including TNF-α and IL-6 following the intra-articular injection of HA@RH-CeO X , accompanied by efficient cartilage regeneration and restored articular function. Overall, this study revealed an approach to in situ modulate the redox homeostasis in inflammatory macrophages and reprogram their polarization states through micelle-complexed biomimetic enzymes, which offers alternative opportunities for the treatment of rheumatoid arthritis.

show abstract

Section: Introductionmentioning

confidence: 99%

Redox Homeostasis Strategy for Inflammatory Macrophage Reprogramming in Rheumatoid Arthritis Based on Ceria Oxide Nanozyme-Complexed Biopolymeric Micelles

Zhou

Chen

et al. 2023

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Therefore, the HNV might act as a nanosponge to absorb inflammatory factors and reduce the inflammatory response. 40 Accordingly, the potential binding capability of HNV@BP to IL-6 or TNF-α, which play prominent roles in initiating and promoting the progression of RA, was tested by enzyme-linked immunosorbent assay (ELISA). As shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Macrophage-derived hybrid exosome-mimic nanovesicles loaded with black phosphorus for multimodal rheumatoid arthritis therapy

Zhao

Song

et al. 2022

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…[272][273][274] Given the pathological features of RA, incorporating contrast agents or drugs into nanomaterials to design nanoprobes or nanodrugs can not only improve drugresponsive release capability but also provide visual information on pathological features and improve therapeutic outcome. [275][276][277][278][279][280] For example, Wang et al developed an inflammation-induced disassembly nanoplatform (DCNR-MTX-CPs/siRNA) wherein conjugated polymer NPs (CPs) were combined with down-conversion nanorods (DCNRs) via bisulfide bridges and then modified using siRNA (Figure 17A). [281] NIR-II FL signal was initially quenched because of the Forster resonance energy transfer (FRET) effect between CPs and DCNRs.…”

Section: Biomarker-responsive Nanotheranostics For Rheumatoid Arthritismentioning

confidence: 99%

Biomarker‐Responsive Nanosystems for Chronic Disease Theranostics

Wang

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

Chronic diseases claim millions of lives every year, and it is of great significance to explore and develop advanced drugs to improve the cure rate of chronic diseases. Nanotheranostics are innovative strategies that enable the integration of diagnostic and therapeutic properties into a single nanosystem. Despite great success in nanotheranostics, their applications of nanotheranostics in nanomedicine are still in their infancy. This is because each disease has its corresponding characteristic pathological microenvironment, which motivates the development of endogenous biomarker-responsive nanosystems to meet the requirements of diagnosis and treatment. Herein, recent progress is presented in biomarker-responsive nanosystems and their biomedical applications. First, biomarker-responsive nanosystems are classified into eight subsections according to the type of chronic diseases, including tumors, cardiovascular diseases, neurological diseases, Wilson's diseases, chronic liver diseases, chronic kidney diseases, diabetes mellitus, and rheumatoid arthritis. In the following, a variety of intriguing applications of biomarkers-responsive nanosystems are briefly elaborated, such as biosensing, diagnosis, therapy, combined theranostics, and early evaluation of therapy effect, etc. Finally, the challenges and future directions from research to clinical translation of these responsive nanosystems are also presented.

show abstract

Nanoengineered therapy aiming at the etiology of rheumatoid arthritis

Cited by 25 publications

References 141 publications

Redox Homeostasis Strategy for Inflammatory Macrophage Reprogramming in Rheumatoid Arthritis Based on Ceria Oxide Nanozyme-Complexed Biopolymeric Micelles

Redox Homeostasis Strategy for Inflammatory Macrophage Reprogramming in Rheumatoid Arthritis Based on Ceria Oxide Nanozyme-Complexed Biopolymeric Micelles

Macrophage-derived hybrid exosome-mimic nanovesicles loaded with black phosphorus for multimodal rheumatoid arthritis therapy

Biomarker‐Responsive Nanosystems for Chronic Disease Theranostics

Contact Info

Product

Resources

About